BRITISH JOURNAL OF CANCER

简称 BRIT J CANCER ·ENGLAND ·出版周期 Semimonthly ·年均收录 377 篇

6.8

最新影响因子

2.50%

自引率

约95%

投稿难度

平均6月

审稿周期

期刊简介

BRITISH JOURNAL OF CANCER是一本国际知名的癌症研究期刊，ISSN号为0007-0920，由英国自然出版集团（Nature Publishing Group）出版，出版地为英国伦敦，出版周期为周刊。该期刊的影响因子较高，属于SCI收录期刊，并在中科院分区中通常位于医学或肿瘤学领域的较高分区（如1区或2区）。该期刊并非完全开放获取（OA），但提供部分开放获取选项。BRITISH JOURNAL OF CANCER的发文特点涵盖癌症的基础、转化和临床研究，涉及肿瘤生物学、诊断、治疗及流行病学等多个领域，尤其注重高质量原创研究和具有临床意义的科学发现。该期刊以严格的同行评审和较高的学术标准著称，但投稿竞争激烈，拒稿率较高，且版面费可能较昂贵，非OA文章的读者访问受限。总体而言，该期刊在癌症研究领域具有较高的学术影响力和声誉，适合发表具有创新性和重要科学价值的研究成果。

影响因子趋势

近期发表

Translational modelling challenges receptor‑occupancy‑based dosing of PD‑1 inhibitors like pembrolizumab 2026-09-05

Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial 2026-09-05

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1 2026-09-04

Radiomics as a spatial context for treatment decision-making in head and neck cancer 2026-09-03

Triglyceride enhancs NSCLC metastasis via lipid β-oxidation by RhoA-driven cytoskeletal remodeling in ECM-constrained microenvironments 2026-09-03

SLFN11 enhances cisplatin sensitivity in pediatric cancer via activation of stress-response and suppression of survival pathways 2026-09-02

Correction: Anti-PDGFRα autoantibody – a novel diagnostic and prognostic marker – may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway 2026-09-01

Why early pathology input matters in biologically rich cancer trials 2026-09-01

ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids 2026-08-31

Correction: Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians 2026-08-31